8-K: Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and reaffirming its cash runway into early 2026.

Summary

• Lisata Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, compared to a net loss of $4.0 million for the same period in 2023.
• Operating expenses decreased by 19.7% to $5.5 million, primarily due to reduced research and development costs and lower general and administrative expenses.
• Research and development expenses were $2.6 million, a decrease of 17.7% compared to the previous year, mainly due to the completion of enrollment in the Phase 2b ASCEND trial.
• General and administrative expenses decreased by 21.3% to $2.9 million, primarily due to one-off severance costs in the prior year and reduced equity expenses.
• The company's cash, cash equivalents, and marketable securities totaled $38.3 million as of June 30, 2024.
• Lisata projects that its available cash will fund operations into early 2026, covering all planned clinical trials through to data readouts.
• The Phase 2b ASCEND trial's top-line data is expected in the fourth quarter of 2024, with the complete data set available by mid-2025.
• The BOLSTER trial achieved complete enrollment in first-line cholangiocarcinoma (CCA) six months ahead of schedule, with topline data expected by mid-2025.
• A second cohort has been added to the BOLSTER trial to evaluate subjects in second-line CCA, with the first patient expected to be enrolled by the fourth quarter of 2024.
• The CENDIFOX trial has completed enrollment in the pancreatic cohort and expects to complete enrollment in the remaining two cohorts by the end of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong clinical progress and a solid cash position. However, the increased net loss and the inherent risks of clinical development temper the overall sentiment.

Positives

• The company has a strong cash position of $38.3 million, which is expected to fund operations into early 2026.
• Multiple clinical trials are progressing well, with key data readouts expected over the next 18 months.
• The company has received several regulatory designations for certepetide, including Orphan Drug and Rare Pediatric Disease designations.
• Operating expenses have decreased significantly, indicating effective cost management.
• Enrollment in the BOLSTER trial for first-line CCA was completed six months ahead of schedule.

Negatives

• The company reported a net loss of $5.0 million for the second quarter of 2024, an increase from the $4.0 million loss in the same period of 2023.
• The company is still in the clinical stage and not generating revenue.

Risks

• The company's future success is dependent on the successful development and commercialization of its product candidates.
• Clinical trial results may not be positive, and regulatory approvals may not be granted.
• The company may need to raise additional capital in the future to fund its operations.
• There are risks associated with the company's reliance on third-party partners for clinical trials and manufacturing.
• The company faces competition from other pharmaceutical companies developing therapies for similar indications.

Future Outlook

Lisata projects that its available cash will fund operations into early 2026, covering all planned clinical trials through to data readouts. The company anticipates multiple key data readouts over the next 18 months, including topline results from the Phase 2b ASCEND trial.

Management Comments

• David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, stated that the second quarter generated strong momentum for Lisata as they continued to advance multiple ongoing and planned clinical studies centered around certepetide.
• Dr. Mazzo added that their continued prudent, strategic financial management allows them to reaffirm their projection that available cash will fund current operations into early 2026.

Industry Context

Lisata is focused on developing therapies for advanced solid tumors, a significant area of unmet medical need. The company's approach of using certepetide to enhance the effectiveness of other anti-cancer drugs aligns with the industry trend of exploring combination therapies and novel drug delivery methods. The company is also targeting pancreatic cancer, a particularly challenging disease with poor survival rates, which is a focus for many companies in the oncology space.

Comparison to Industry Standards

• Lisata's approach of using certepetide to enhance drug delivery is similar to other companies exploring antibody-drug conjugates (ADCs) and other targeted therapies, such as Immunomedics (acquired by Gilead) with Trodelvy and Seagen (acquired by Pfizer) with Adcetris.
• The company's focus on pancreatic cancer is comparable to companies like Halozyme Therapeutics, which is developing a drug delivery technology for pancreatic cancer treatments.
• The reported cash runway into early 2026 is a positive sign, as many biotech companies struggle with funding, especially during clinical development phases. This is comparable to companies like Mirati Therapeutics, which has also focused on maintaining a strong cash position to fund its clinical programs.
• The decrease in operating expenses is a positive sign, as many biotech companies struggle with high burn rates. This is comparable to companies like Blueprint Medicines, which has also focused on cost management during its clinical development phase.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and clinical trial results.
• Employees will be impacted by the company's operational and financial decisions.
• Patients with advanced solid tumors may benefit from the development of new therapies.
• The company's partners will be impacted by the progress of clinical trials and commercialization efforts.

Next Steps

• The company will continue to enroll patients in ongoing clinical trials.
• Lisata will report top-line data from the Phase 2b ASCEND trial in the fourth quarter of 2024.
• The company will enroll the first patient in the second cohort of the BOLSTER trial by the fourth quarter of 2024.
• Lisata will complete enrollment in the CENDIFOX trial by the end of 2024.
• The company will enroll the first patient in the FORTIFIDE trial by the first half of 2025.

Key Dates

Keywords

Certepetide, Pancreatic Cancer, Solid Tumors, Clinical Trials, Orphan Drug Designation, Rare Pediatric Disease Designation, Drug Development, Pharmaceutical, Oncology, Metastatic Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma